Stifel reiterates Compugen stock rating on ovarian trial update

Stifel reiterated a Buy rating and $4.00 price target on Compugen (CGEN) after its investor event, citing a 73% upside potential. The event focused on the MAIA-ovarian trial and expanded UnigenX platform. Compugen reported Q2 revenue of $2.6M, a net loss of $7.0M, and a strong cash position. H.C. Wainwright also maintained a Buy rating with a $4.00 target.

Original reporting
Published Oct 6, 2026, 12:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CGEN
Neutral
medium confidence
Mentioned
$CGEN
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CGENNeutralLow
01

Why it matters

The analyst's reiteration reinforces existing price expectations but does not introduce fresh material that would shift the stock significantly.

02

Market read

Limited relevance; primarily of interest to niche biotech investors.

03

What to watch

Potential competitive landscape in ovarian cancer therapies and the need for actual trial results to validate the upside.

Relevance 4/10Novelty 2/10Timing: none

Background

Compugen (NASDAQ:CGEN) is a small‑cap biotech focused on cancer immunotherapy. The article repeats an analyst's rating and target after a virtual event that provided trial progress details but no new data.

Company-level read

Ticker impact

$CGENNeutralMedium confidence
Context

Stifel reiterated a Buy rating and $4.00 price target for Compugen after its virtual investor event discussing the MAIA-ovarian trial update.

Expected impact

likely modest buying pressure as the market prices in the reiterated target.

Evidence & confidence

The rating and target are not new information; they restate existing expectations, offering limited actionable insight.

Market effects

Minimal impact on the broader biotech sector; trial update is a routine progress report.

No discernible regional effect.

Limited to investors tracking early‑stage oncology biotech.

Counterpoint

The reiteration may be overly optimistic given the trial is still early and no efficacy data released.

Key entities

  • Compugen Ltd.

    Biotech firm developing ovarian cancer therapy.

  • Stifel

    Equity research firm issuing the Buy rating.

Related articles

$CGENMed

Compugen stock maintained at Buy by H.C. Wainwright, $4 target

H.C. Wainwright maintained a Buy rating and $4.00 target on Compugen (CGEN) after Q3 results. The stock trades at $2.09, up 9% in a week and 37% YTD. Compugen completed enrollment for its MAIA-ovarian study, with results expected by Q1 2027. Q3 revenue was $3.8M, up from $1.9M YoY but below estimates. The company expects sufficient cash to support operations through 2029.

$CGENMed

What Compugen (CGEN) Said on Its Q3 Earnings Call

Compugen (CGEN) reported Q3 revenue of $3.8M, up from $1.9M YoY. The company discussed milestones for its partnered programs with AstraZeneca and Gilead, including potential payments and royalties. Compugen also introduced UnigenX, an expansion of its AI-powered discovery engine. The net loss narrowed to $5.8M, or $0.06 per share, with $117.5M in cash equivalents.

$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.